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Background

Methods

Fibromyalgia refers to a rheumatic condition
experienced as pain all over the body without a
specific cause. This is considered a diagnosis of
exclusion. This classification seems to suggests that
any treatment options for it are purely symptomatic
and are not disease targeted. Its complex diagnosis
and underlying pathology contribute to the challenge
of medically addressing fibromyalgia. Without a
strict cause, fibromyalgia is often treated
symptomatically with CBT and SNRIs. However,
recent research suggests that existing therapeutic
approaches are not very effective, especially when
considering long term benefits for this chronic
condition. This beckons for novel treatment options
for these patients. Microglia have been implicated in
previous studies for their role in neuropathic pain
mechanisms. By considering recent advances in our
knowledge of microglia, this research aims to
determine the involvement of microglia in
fibromyalgia pathology to hopefully identify a novel
treatment target.

A review was conducted using secondary analysis to
investigate the efficacy of microglia-attenuating
treatment models in treating neuropathic pain conditions,
with emphasis on fibromyalgia. Data collection was
done by performing searches on the national scientific
database, PubMed. A variety of keywords were used to
narrow down research associated with microglia and
fibromyalgia. Certain search terms were used such as
“microglia AND fibromyalgia”, “microglia-based
treatment”, “central sensitization AND neuropathic pain”
and “microglial attenuation AND neuropathic pain” were
used to isolate relevant information to the research topic.
MeSH Terms were utilized and implemented into search
criteria when appropriate. Special emphasis was placed
on search results between the years 2020-2022.
Information on microglial activation, attenuation models,
and involvement in mechanisms was extracted.
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Objectives
This research aims to explore the role of microglia
in fibromyalgia pathophysiology with the intention
of suggesting a novel treatment option for
fibromyalgia patients that is disease modifying
instead of symptomatic.
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Results
Studies have shown that a combination of melatonin
and folic acid could significantly reduce behavioral
effects and oxidative stress in a fibromyalgia model
that also showed significant reduction in microglia
activation. Minocycline, which was shown to reliably
ameliorate microglial activity, was shown to attenuate
mechanical hyperalgesia and allodynia. Purinergic
receptor antagonist Brilliant Blue G could inactivate
microglial through P2X7R block and attenuate
microglial activation and pain related behaviors. These
findings highlight that microglia may have a role in the
pathology underlying fibromyalgia and may be an
important consideration as a therapeutic target.

